SINOVAC BIOTECH LTD(SVA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

SINOVAC BIOTECH LTD (SVA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SVA at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,733 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), SINOVAC BIOTECH LTD reports quarterly revenue of $386.0M, net income of $-198.8M, free cash flow of $-561.1M. Top institutional holders of SVA by reported 13-F value include ORBIMED ADVISORS, Vivo Capital, Neumann Advisory Hong Kong Ltd, based on the most recent SEC filings. SVA trades on the Nasdaq exchange and files with the SEC under CIK 1084201. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SINOVAC BIOTECH LTD directly from SEC EDGAR.